Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Subcutaneous (SC) Abatacept Clear all

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 63 more

Conditions: Alopecia Areata
Interventions: Abatacept, placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: IgG4-related Disease
Interventions: Abatacept; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis, Chronic Hepatitis B
Interventions: Abatacept, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis (RA)
Interventions: abatacept, Methotrexate (MTX); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more

Conditions: Type 1 Diabetes
Interventions: Abatacept; Drug
Lead sponsor: Sandra Lord, MD; Other
Eligibility: 6 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Seattle, Washington • Milwaukee, Wisconsin

Conditions: Transplantation
Interventions: belatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 42
States / cities: Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Adalimumab, Methotrexate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Fullerton, California • Los Alamitos, California • Aurora, Colorado + 11 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Dinesh Khanna, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept or Placebo (both as IV & SC solution), Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 5
States / cities: Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more

Conditions: Alopecia Areata
Interventions: Abatacept; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Rituximab-pvvr, Abatacept, Sterile Sodium Chloride; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 17
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
Interventions: Abatacept subcutaneous, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Beverly Hills, California • Orange, California + 22 more

Search by objective public record fields.

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Methotrexate-Inadequate Response Study

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Safety and Efficacy of Abatacept in IgG4-Related Disease

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Early Markers of Disease and Response to Therapy

Subcutaneous Pharmacokinetics of Belatacept

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

Study of COYA 302 for the Treatment of ALS

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy